Dr. Noah Israel Goldfarb, MD

Dr. Goldfarb practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Dr. Goldfarb's NPI, 1417188939, was assigned on July 31, 2009. Dr. Goldfarb graduated from State University of New York at Stony Brook, School of Medicine in 2009. Dr. Goldfarb holds Minnesota license 53568.

Dr. Goldfarb's primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Dr. Goldfarb's primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. Dr. Goldfarb is also affiliated with M Health Fairview St. John's Hospital. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Goldfarb to 5 more group practices and clinics, 5 medical groups, 1 dialysis center and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldfarb practices, 9 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Goldfarb's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Goldfarb is licensed in Minnesota.

CMS data shows 25 Medicare services from Dr. Goldfarb across 1 procedure code in 2024, all of them office visits, for 33 Medicare patients. Medicare paid $2,431 for them. Every service was in an office.

CMS counts 33 Medicare patients who saw Dr. Goldfarb in 2024. 73% of them have mood disorders, and 67% have anxiety. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goldfarb's median patient age at 43, with 55% women.

In 2024, Dr. Goldfarb wrote 528 Medicare Part D claims for 55 patients. 62% of them were for generic drugs. CMS names the drug for 352 of them, across 18 drugs with 11 or more claims each, at $2,620,729 in total drug cost. In 2023, CMS named 146 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Goldfarb for performance year 2024, reported as part of a group. Dr. Goldfarb accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldfarb as offering telehealth.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 53 papers to Dr. Goldfarb, published from 2012 to 2025. 2022 was the busiest year, with 7. The most frequent topics are Hidradenitis Suppurativa, Skin Neoplasms and Carcinoma, Squamous Cell. Dr. Goldfarb has published most often in Br J Dermatol. Dr. Goldfarb's most frequent co-authors are Afsaneh Alavi, MD, Michelle Anne Lowes, MD, PhD and Ronda Samir Farah, MD.

CMS Open Payments shows 23 general payments to Dr. Goldfarb from 6 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 92% of the total. UCB, Inc. paid the most, $13,841. It also lists 2 research payments totaling $4,351 from 2023 to 2024.

Dr. Goldfarb graduated from State University of New York at Stony Brook, School of Medicine in 2009.